Open Access

Dr Bechara received honoraria from AbbVie, Novartis, and Janssen for advisory board and speaker services, and his department received grants from AbbVie, Novartis, UCB, InflaRx, Incyte, and Janssen for his participation as an investigator. Dr Podda reported personal fees from AbbVie and grants from AbbVie paid to Klinikum Darmstadt during the conduct of the study; personal fees and grants paid to Klinikum Darmstadt from Beiersdorf, Bristol Myers Squibb, CSL Behring, Galderma, Janssen-Cilag, Leo Pharma, Novartis, MSD, USB, Boehringer Ingelheim, Eli Lilly and Company, and InflaRx outside the submitted work. Dr Prens received honoraria from AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen-Cilag, Galderma, InflaRx, Novartis, UCB, Regeneron, and Pfizer for speaker and advisory board services and received investigator-initiated grants (paid to the Erasmus MC) from AbbVie, Celgene, Janssen-Cilag, and UCB. Dr Horváth reported grants from Janssen-Cilag, AbbVie, Novartis, UCB Pharma, and Leo Pharma paid to their institution during the conduct of the study; grants from Solenne BV, Celgene, Akari Therapeutics, Philips, Roche, Regeneron, and Sanofi paid to their institution outside the submitted work; and personal fees from Janssen-Cilag, AbbVie, Novartis Pharma, UCB Pharma, Leo Pharma, Solenne BV, Celgene, Akari Therapeutics, Philips, Roche, Regeneron, and Sanofi paid to their institution. Dr Giamarellos-Bourboulis reported grants from AbbVie for the SHARPS study to the National and Kapodistrian University of Athens during the conduct of the study; grants from Abbott, InflaRx, XBiotech, Astellas Pharma, Axis Shield, Horizon 2020 ImmunoSep, bioMérieux, FrameWork 7 HemoSpec, and Horizon 2020 Marie Curie ITN European Sepsis Academy; personal fees from Abbott, XBiotech, Angelini Pharma, Pfizer, and ThermoFisher outside the submitted work; and honoraria from MSD. Dr Alavi reported grants from AbbVie during the conduct of the study; personal fees from Novartis, Janssen, Kymera Therapeutics, and AbbVie outside the submitted work; and has acted as a consultant, advisor, and/or received research funding from Asana, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Galderma, Genentech, Glenmark, Incyte, InflaRx, Leo Pharma, Novartis, Regeneron, UCB, and Valeant. Dr Szepietowski is an advisory board member of AbbVie, Leo Pharma, Novartis, Pierre Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals, and Trevi; principal investigator for AbbVie, Novartis, Menlo Therapeutics, Trevi, Janssen, Merck, Regeneron, Amgen, Boehringer Ingelheim, Galapagos, Galderma, InflaRx, Kymab, Pfizer, UCB, Helm, and Incyte; speaker for AbbVie, Novartis, Janssen, Eli Lilly, Sanofi Genzyme, Sun Pharma, and Berlin-Chemie Menarini; and reported personal fees from AbbVie during the conduct of the study and outside the submitted work. Dr Kirby reported personal fees from AbbVie, ChemoCentryx, Incyte, Novartis, Janssen, and UCB Pharma outside the submitted work. Dr Geng reported owns AbbVie stock as an employee. Dr Jean reported being a former employee of AbbVie and owns stock or stock options. Dr Jemec reported grants from AbbVie, InflaRx, Novartis, Janssen-Cilag, CSL Behring, Afyx, Regeneron, and Leo Pharma; personal fees from UCB Pharma, Incyte, and ChemoCentryx during the conduct of the study; personal fees from Coloplast, Novartis, and Leo Pharma outside the submitted work; a patent for a probiotic pending; is editor in chief of Dermatology; advisor at Miiskin and Henlez; honoraria from Kymera and VielaBio. Dr Zouboulis reported grants from AbbVie paid to the Dessau Medical Center during the conduct of the study; grants from AbbVie paid to the Dessau Medical Center outside the submitted work; personal fees from AbbVie outside the submitted work; personal consultation/lecture/advisory board honoraria from Almirall, Bayer, Celgene, Galderma, GlaxoSmithKline/Stiefel, Idorsia, Incyte, InflaRx, Janssen, Novartis, Pierre Fabre, PPM Pharma, Regeneron, Sobi, UCB; and fees paid to the Dessau Medical Center for participation at clinical studies from Advanced Oxygen Therapy Inc, AstraZeneca, Galderma, InflaRx, NAOS-Bioderma, Novartis, PPM Pharma, Relaxera, and UCB Pharma.

AbbVie funded this study.